Eli Lilly's JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 patients, but had a significant effect on mortality, a secondary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback